- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- everolimus, anastrozole, letrozole, tamoxifen citrate, fulvestrant, megestrol acetate
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 887
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- BMS-663068, Oral Contraceptive, Loestrin 1.5/30
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Miami, Florida • San Antonio, Texas
- Conditions
- Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
- Interventions
- Futibatinib, Futibatinib plus Fulvestrant
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • San Francisco, California • Fort Myers, Florida + 12 more
- Conditions
- Advanced HR+/HER2- Breast Cancer
- Interventions
- IEV407, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Kansas City, Kansas • Dallas, Texas
- Conditions
- Progesterone, Estrogens, Hearing, Psychoacoustics, Auditory Perceptual Disorders
- Interventions
- Hormone Replacement Therapy - HRT
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 60 Years to 86 Years · Female only
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2005
- U.S. locations
- 2
- States / cities
- Rochester, New York
- Conditions
- Breast Cancer
- Interventions
- Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Menopause, Hot Flashes
- Interventions
- Soy Phytoestrogen, Estradiol, Medroxyprogesterone Acetate (MPA), Soy Placebo, MPA Placebo
- Dietary Supplement · Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy Females
- Interventions
- PF-06651600, Ethinyl estradiol (EE) and levonogestrel (LN)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Coral Gables, Florida • Miami, Florida
- Conditions
- Arterial Stiffening, Aging, Menopause
- Interventions
- GnRHant - Ganirelix acetate, Transdermal estradiol patch, Transdermal placebo patch
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- HER2-positive Metastatic Breast Cancer
- Interventions
- Alpelisib, Tucatinib, Fulvestrant
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Fort Collins, Colorado • New Orleans, Louisiana + 1 more
- Conditions
- Contraception
- Interventions
- LPRI424 (dienogest/ethinylestradiol)
- Drug
- Lead sponsor
- Insud Pharma
- Industry
- Eligibility
- 13 Years to 45 Years · Female only
- Enrollment
- 1,034 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Savannah, Georgia
- Conditions
- Premenopause, Healthy
- Interventions
- Estradiol steroid infusion, Progesterone steroid infusion
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Neoplasms, Neoplasm Metastasis
- Interventions
- LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 129
- States / cities
- Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 110 more
- Conditions
- HIV Infections
- Interventions
- VH4524184, Loestrin
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- SNV4818, Fulvestrant, Palbociclib
- Drug
- Lead sponsor
- Pikavation Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- estradiol, ethinyl estradiol, medroxyprogesterone, norethindrone
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 0 Years and older · Female only
- Enrollment
- 970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
- Interventions
- combined oral contraceptives
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 64 participants
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- fulvestrant, tipifarnib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- therapeutic estradiol, exemestane, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Biological · Drug · Other
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Prostate Cancer
- Interventions
- Estramustine, Etoposide, Paclitaxel
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- HR+/HER2-negative Breast Cancer
- Interventions
- TOS-358, Fulvestrant, Palbociclib, Ribociclib
- Drug
- Lead sponsor
- Totus Medicines
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 4 more
- Conditions
- HIV/AIDS, Gender, Behavior and Behavior Mechanisms
- Interventions
- TDF/FTC
- Drug
- Lead sponsor
- Hektoen Institute for Medical Research
- Other
- Eligibility
- 15 Years to 24 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
- Interventions
- Levonorgestrel intrauterine system, Combined oral contraceptives
- Device · Drug
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Menopausal and Other Perimenopausal Disorders
- Interventions
- Mirena, Estradiol, Placebo Gel
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years to 52 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado